Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.
| Revenue (Most Recent Fiscal Year) | $39.01M |
| Net Income (Most Recent Fiscal Year) | $-3.82M |
| PE Ratio (Current Year Earnings Estimate) | 58.58 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.97 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 19.34 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6.92% |
| Net Margin (Trailing 12 Months) | -7.10% |
| Return on Equity (Trailing 12 Months) | -0.73% |
| Return on Assets (Trailing 12 Months) | -0.22% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.77 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.16 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.14 |
| Inventory Turnover (Trailing 12 Months) | 1.73 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.89 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 26.82M |
| Free Float | 22.52M |
| Market Capitalization | $463.41M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | 1.13 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.03% |
| Percentage Held By Institutions (Latest 13F Reports) | 27.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |